Company Takes Charge in Effort to Convert Embryonic Stem Cells to Islets

Novocell, Inc., a San Diego, California-based stem cell engineering company, announced on October 19, 2006, the development of a process that “efficiently converts human embryonic stem cells into insulin-producing pancreatic endocrine cells.”

“Such an approach could provide a means to produce sufficient quantities of insulin-producing cells for transplantation into patients with type 1 diabetes,” writes Novocell in a press release, “a treatment that offers a potential therapy for this disease.”

* * *

Source: Novocell, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.